These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7743695)

  • 1. Clinical efficacy of ibopamine in patients with chronic heart failure.
    Metra M; Dei Cas L
    Clin Cardiol; 1995 Mar; 18(3 Suppl I):I22-31. PubMed ID: 7743695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurohormonal and hemodynamic effects of ibopamine.
    Pouleur H
    Clin Cardiol; 1995 Mar; 18(3 Suppl I):I17-21. PubMed ID: 7743694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group.
    Brouwer J; van Veldhuisen DJ; Man in 't Veld AJ; Dunselman PH; Boomsma F; Haaksma J; Lie KI
    J Am Coll Cardiol; 1995 Oct; 26(4):983-90. PubMed ID: 7560628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.
    Spencer C; Faulds D; Fitton A
    Drugs Aging; 1993; 3(6):556-84. PubMed ID: 7906158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure.
    Dei Cas L; Metra M; Visioli O
    Am J Cardiol; 1992 Sep; 70(6):629-34. PubMed ID: 1354938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine.
    Metra M; Missale C; Spano PF; Cas LD
    J Cardiovasc Pharmacol; 1995 May; 25(5):732-40. PubMed ID: 7630152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure.
    Lieverse AG; Girbes AR; Van Veldhuisen DJ; Smit AJ; Zijlstra JG; Meijer S; Lie KI; Reitsma WD
    Eur Heart J; 1995 Jul; 16(7):937-42. PubMed ID: 7498209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of captopril and ibopamine in mild to moderate heart failure.
    Dohmen HJ; Dunselman PH; Poole-Wilson PA
    Heart; 1997 Sep; 78(3):285-90. PubMed ID: 9391292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
    Szabó BM; van Veldhuisen DJ; van der Burgh PH; Kruik J; Girbes AR; Lie KI
    J Card Fail; 1996 Sep; 2(3):185-92. PubMed ID: 8891856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.
    Hampton JR; van Veldhuisen DJ; Kleber FX; Cowley AJ; Ardia A; Block P; Cortina A; Cserhalmi L; Follath F; Jensen G; Kayanakis J; Lie KI; Mancia G; Skene AM
    Lancet; 1997 Apr; 349(9057):971-7. PubMed ID: 9100622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of ibopamine, an alternative substance for treatment of chronic heart failure.
    Holubarsch C; Just H
    Cardiology; 1990; 77 Suppl 5():1-8. PubMed ID: 2279251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor.
    Rousseau MF; Konstam MA; Benedict CR; Donckier J; Galanti L; Melin J; Kinan D; Ahn S; Ketelslegers JM; Pouleur H
    Am J Cardiol; 1994 Mar; 73(7):488-93. PubMed ID: 7908164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic and neurohumoral effects of ibopamine in patients with chronic congestive heart failure.
    López-Sendón J
    Cardiology; 1990; 77 Suppl 5():9-21. PubMed ID: 1980634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT).
    van Veldhuisen DJ; Man in 't Veld AJ; Dunselman PH; Lok DJ; Dohmen HJ; Poortermans JC; Withagen AJ; Pasteuning WH; Brouwer J; Lie KI
    J Am Coll Cardiol; 1993 Nov; 22(6):1564-73. PubMed ID: 7901256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects.
    López-Sendón J
    Am J Med; 1991 May; 90(5B):43S-49S. PubMed ID: 1675551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibopamine--how should it be used?
    Bussmann WD; Wienhöfer K; Frik R
    Cardiology; 1988; 75 Suppl 1():126-37. PubMed ID: 3069210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
    Dei Cas L; Metra M; Nodari S; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S111-7. PubMed ID: 2483436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure.
    Sannia L; Ibba GV; Castellaccio M; Dore L
    Arzneimittelforschung; 1986 Feb; 36(2A):355-9. PubMed ID: 3707649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibopamine in the treatment of heart failure.
    Man in't Veld AJ
    Am J Med; 1991 May; 90(5B):50S-54S. PubMed ID: 1675552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure.
    van Veldhuisen DJ; van Gilst WH; de Smet BJ; de Graeff PA; Scholtens E; Buikema H; Girbes AR; Wesseling H; Lie KI
    Cardiovasc Drugs Ther; 1994 Apr; 8(2):245-50. PubMed ID: 7918137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.